Show
Sort by
-
Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL)
-
Long-term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) With Relapsed/Refractory (r/r) Follicular Lymphoma (FL) Treated With Tisagenlecleucel in the ELARA Trial
-
Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and >= 2 prior lines of therapy : key results of the phase-II expansion
(2022) ONCOLOGY RESEARCH AND TREATMENT. In Oncology Research and Treatment 45(Supplement 2). p.50-51 -
Nivolumab in combination with gemcitabine and oxaliplatin (GemOx) in relapse/refractory T-cell lymphoma : preliminary results of the experimental arm of the NIVEAU trial
(2021) ONCOLOGY RESEARCH AND TREATMENT. In Oncology Research and Treatment 44(supplement 2). p.128-129 -
Glofitamab in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) : durable complete responses and manageable safety observed at clinically relevant doses in Phase I dose escalation
(2020) ONCOLOGY RESEARCH AND TREATMENT. In Oncology Research and Treatment 43(Supplement 4). p.58-59